Quarter
Charts

The Oncology Institute, Inc. — Key Metrics

2 years of history · ending 2025-12-31 · SEC EDGAR

Income StatementCash FlowBalance SheetKey Metrics

Forensics

Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.

F-Score (Piotroski 0-9)

Z-Score (Altman; <1.81 = distress)

Per Share Metrics

Turnover & Efficiency Analysis (days)

Expense Ratios

Working Capital Analysis

Valuation Multiples

Enterprise Value Multiples

52-Week Range

Trailing Returns

ROIC vs WACC

Yields

Capital Deployment Yields

Liquidity & Leverage Ratios

Earnings Quality (OCF/NI · FCF/NI · Sloan Accruals)

EPS (Diluted)
$-1
Book Value Per Share
$-0
Free Cash Flow Per Share
$-0
Cash Per Share
—
Revenue Per Share
$5
OCF Per Share
$-0
Return on Equity
999.2%
Return on Assets
-35.9%
Return on Invested Capital
-36.0%
Debt to Equity
-4.92
Current Ratio
1.59
Quick Ratio
1.35
Asset Turnover
2.98
Days Sales Outstanding
42.83
SBC / Revenue
0.9%
Capex / Revenue
0.6%
Working Capital
$42M
Net Current Asset Value
$-68M
Invested Capital
$62M
OCF / Net Income
0.41
FCF / Net Income
0.46
Accruals Ratio (Sloan)
-21.9%
Net Debt
$77M
Net Debt / EBITDA
-2.66
Interest Coverage
-3.20
Cash Coverage
-2.18
Capex Coverage
-7.68
Tangible Common Equity
$-34M
TCE / Total Assets
-20.6%
Goodwill / Total Assets
4.4%
NOPAT
$-29M
Cash ROIC
-35.1%
WC / Revenue
8.3%
Capex / D&A
0.46
Reinvestment Rate
10.4%
Total Payout Ratio
0.0%
Asset Growth vs Revenue Growth
-32.5%
Revenue 5Y CAGR
21.8%
Stock Price (FY-end)
$4
Market Cap
$329M
P/E Ratio
—
P/S Ratio
0.65
P/B Ratio
6.46
P/TB Ratio
—
P/OCF Ratio
—
Enterprise Value
$406M
EV / Sales
0.81
FCF Yield
-8.4%
Shareholder Yield
-1.4%
Buyback Yield
0.0%
Capex Yield
1.0%
Graham Number
—
Shares Variation (YoY)
23.1%
Beta (5Y)
1.04
Cost of Equity
9.7%
Cost of Debt (after tax)
11.5%
WACC
10.0%
ROIC - WACC Spread
-46.0%
52W High
$5
52W Low
$0
Trailing Return 1Y
1023.0%
Trailing Return 5Y
-67.3%
F-Score (Piotroski)
4.00
Z-Score (Altman)
1.42

Earnings Forecasts

Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).

Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.

EPS — Consensus vs Actual

Revenue — Consensus vs Actual

Stock Price on Earnings Dates

The Oncology Institute, Inc. — Effective Tax Rate ReconciliationNEW

Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.

Reconciliation LineFY2025
Federal Statutory Rate21.00%
State & Local Income Taxes0.00%
Foreign Rate Differential—
Other Adjustments-0.22%
SBC (Nondeductible)-0.45%
Valuation Allowance Change-14.90%
Effective Tax Rate0.21%

Cash vs Accrual

ItemFY2025
Income Tax Expense (Accrual)−$131.0K
Income Taxes Paid (Cash)—